ADM Q1 2026 Earnings Call Transcript

ADM reported Q1 adjusted EPS of $0.71 and raised full-year 2026 adjusted EPS guidance to $4.15-$4.70 from $3.60-$4.25, citing stronger crush, ethanol, and nutrition results. Segment operating profit reached $764 million, with Carbohydrate Solutions up 48% and Nutrition up 42%, while AS&O was pressured by a $275 million negative mark-to-market impact that management expects to largely reverse. The company also highlighted 300,000 metric tonnes of CO2 sequestered, a projected $150 million 45Z tax credit benefit, and continued dividend discipline.

Analysis

ADM is effectively telling the market that policy is now a cash-flow catalyst rather than a headline risk: the RVO reset and 45Z clarity are tightening nearby biofuel economics fast enough to pull forward crush and ethanol margins. The second-order winner is not just ADM, but the whole “molecules-to-fuels” complex tied to soybean oil, RINs, and renewable diesel utilization; plants with flexible feedstock access and logistics optionality should see better spread capture than pure-play crushers or standalone ethanol assets.

The most important nuance is that the quarter’s downside in AS&O looks more like timing than demand destruction, which means the reported miss can reverse over the next 1-2 quarters if commodity curves stay constructive. That creates a near-term earnings step-up setup into Q2, but also a risk that the market is over-anchoring on one-time reversal while underestimating how much of the benefit is already embedded in the forward curve. If crush spreads normalize faster than ADM expects, the company may be forced to “give back” some of the optics via fresh mark-to-market volatility.

The hidden issue is that ADM’s better guide depends on multiple moving parts lining up simultaneously: China resuming normal buying, ethanol staying strong, and consumer softening in starch/sweeteners not worsening. That makes the setup more fragile in the back half than the headline EPS raise suggests, especially with higher energy, FX, and tariff sensitivity. My read is the stock should rerate on near-term earnings power, but a sustained multiple expansion needs evidence that Nutrition and biosolutions can offset commodity cyclicality rather than just smooth it.

Key Decisions for Investors

• Go long ADM on a 4-8 week horizon into Q2 print; use a $1.5-$2.0 upside window from guidance revision and mark-to-market reversal, but trim if crush spreads flatten or corn/soy complex rolls over.
• Pair trade: long ADM / short TSN over 1-2 quarters as ADM has policy-driven margin upside while protein processors face more input-cost and demand volatility; target modest spread capture with lower beta than outright ags exposure.
• Buy ADM Jan-2027 call spreads for a cleaner way to express the 45Z/RVO multi-quarter tailwind; risk is policy fade or commodity mean reversion, reward is multiple expansion if earnings reset higher again.
• If already long, hedge with a short position in a pure-play ethanol or biodiesel proxy for 1-3 months, since ADM is better positioned to monetize policy than smaller operators with weaker logistics and procurement scale.